Higher levels of Pseudomonas aeruginosa LasB elastase expression are associated with early-stage infection in cystic fibrosis patients.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 08 2023
30 08 2023
Historique:
received:
28
02
2023
accepted:
24
08
2023
medline:
1
9
2023
pubmed:
31
8
2023
entrez:
30
8
2023
Statut:
epublish
Résumé
Pseudomonas aeruginosa is a common pathogen in cystic fibrosis (CF) patients and a major contributor to progressive lung damage. P. aeruginosa elastase (LasB), a key virulence factor, has been identified as a potential target for anti-virulence therapy. Here, we sought to differentiate the P. aeruginosa isolates from early versus established stages of infection in CF patients and to determine if LasB was associated with either stage. The lasB gene was amplified from 255 P. aeruginosa clinical isolates from 70 CF patients from the Toulouse region (France). Nine LasB variants were identified and 69% of the isolates produced detectable levels of LasB activity. Hierarchical clustering using experimental and clinical data distinguished two classes of isolates, designated as 'Early' and 'Established' infection. Multivariate analysis revealed that the isolates from the Early infection class show higher LasB activity, fast growth, tobramycin susceptibility, non-mucoid, pigmented colonies and wild-type lasR genotype. These traits were associated with younger patients with polymicrobial infections and high pFEV
Identifiants
pubmed: 37648735
doi: 10.1038/s41598-023-41333-9
pii: 10.1038/s41598-023-41333-9
pmc: PMC10468528
doi:
Substances chimiques
Pancreatic Elastase
EC 3.4.21.36
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14208Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIEHS NIH HHS
ID : 27302C0028
Pays : United States
Organisme : Wellcome Trust
ID : WT224842
Pays : United Kingdom
Informations de copyright
© 2023. Springer Nature Limited.
Références
Bell, S. C. et al. The future of cystic fibrosis care: A global perspective. Lancet Respir. Med. 8, 65–124 (2020).
pubmed: 31570318
Sherrard, L. J., Tunney, M. M. & Elborn, J. S. Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis. Lancet 384, 703–713 (2014).
pubmed: 25152272
Stover, C. K. et al. Complete genome of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406, 959–964 (2000).
pubmed: 10984043
Rossi, E. et al. Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis. Nat. Rev. Microbiol. 19, 331–342 (2021).
pubmed: 33214718
Winstanley, C., O’Brien, S. & Brockhurst, M. A. Pseudomonas aeruginosa evolutionary adaptation and diversification in cystic fibrosis chronic lung infections. Trends Microbiol. 24, 327–337 (2016).
pubmed: 26946977
pmcid: 4854172
Nguyen, D. & Singh, P. K. Evolving stealth: Genetic adaptation of Pseudomonas aeruginosa during cystic fibrosis infections. Proc. Natl. Acad. Sci. 103, 8305–8306 (2006).
pubmed: 16717189
pmcid: 1482488
Boutin, S. et al. Chronic but not intermittent infection with Pseudomonas aeruginosa is associated with global changes of the lung microbiome in cystic fibrosis. Eur. Respir. J. 50, 1701086 (2017).
pubmed: 28982777
Araújo, D. et al. The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. Eur. Respir. J. 51, 1701953 (2018).
pubmed: 29386336
Eklöf, J. et al. Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease. Clin. Microbiol. Infect. 28, 990–995 (2022).
pubmed: 35124256
Sawa, T. The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: From bacterial pathogenesis to host response. J. Intensive Care 2, 10 (2014).
pubmed: 25520826
pmcid: 4267601
Strateva, T. & Mitov, I. Contribution of an arsenal of virulence factors to pathogenesis of Pseudomonas aeruginosa infections. Ann. Microbiol. 61, 717–732 (2011).
Nadal Jimenez, P. et al. The multiple signaling systems regulating virulence in Pseudomonas aeruginosa. Microbiol. Mol. Biol. Rev. 76, 46–65 (2012).
pmcid: 3294424
Lee, J. & Zhang, L. The hierarchy quorum sensing network in Pseudomonas aeruginosa. Protein Cell 6, 26–41 (2015).
pubmed: 25249263
Papenfort, K. & Bassler, B. L. Quorum sensing signal–response systems in Gram-negative bacteria. Nat. Rev. Microbiol. 14, 576–588 (2016).
pubmed: 27510864
pmcid: 5056591
Wang, Y. et al. Characterization of lasR-deficient clinical isolates of Pseudomonas aeruginosa. Sci. Rep. 8, 13344 (2018).
pubmed: 30190495
pmcid: 6127196
Gambello, M. J. & Iglewski, B. H. Cloning and characterization of the Pseudomonas aeruginosa lasR gene, a transcriptional activator of elastase expression. J. Bacteriol. 173, 3000–3009 (1991).
pubmed: 1902216
pmcid: 207884
Cabeen, M. T. Stationary phase-specific virulence factor overproduction by a lasR mutant of Pseudomonas aeruginosa. PLoS One 9, e88743 (2014).
pubmed: 24533146
pmcid: 3923063
Ahmed, S. A. K. S. et al. Natural quorum sensing inhibitors effectively downregulate gene expression of Pseudomonas aeruginosa virulence factors. Appl. Microbiol. Biotechnol. 103, 3521–3535 (2019).
pubmed: 30852658
pmcid: 6449319
Everett, M. J. & Davies, D. T. Pseudomonas aeruginosa elastase (LasB) as a therapeutic target. Drug Discov. Today 26, 2108–2123 (2021).
pubmed: 33676022
LaFayette, S. L. et al. Cystic fibrosis-adapted Pseudomonas aeruginosa quorum sensing lasR mutants cause hyperinflammatory responses. Sci. Adv. 1, e1500199 (2015).
pubmed: 26457326
pmcid: 4597794
Agaronyan, K. et al. Tissue remodeling by an opportunistic pathogen triggers allergic inflammation. Immunity 55, 895-911.e10 (2022).
pubmed: 35483356
pmcid: 9123649
Cigana, C. et al. Pseudomonas aeruginosa elastase contributes to the establishment of chronic lung colonization and modulates the immune response in a murine model. Front. Microbiol. 11, 620819 (2021).
pubmed: 33510733
pmcid: 7836092
Green, D. M. et al. Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients. Respir. Res. 11, 140 (2010).
pubmed: 20932301
pmcid: 2964615
McKone, E. F., Emerson, S. S., Edwards, K. L. & Aitken, M. L. Effect of genotype on phenotype and mortality in cystic fibrosis: A retrospective cohort study. Lancet 361, 1671–1676 (2003).
pubmed: 12767731
Lee, T. W. R., Brownlee, K. G., Conway, S. P., Denton, M. & Littlewood, J. M. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J. Cyst. Fibros. 2, 29–34 (2003).
pubmed: 15463843
Proesmans, M. et al. Evaluating the “Leeds criteria” for Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur. Respir. J. 27, 937–943 (2006).
pubmed: 16707392
Winsor, G. L. et al. Enhanced annotations and features for comparing thousands of Pseudomonas genomes in the Pseudomonas genome database. Nucleic Acids Res. 44, D646–D653 (2016).
pubmed: 26578582
Everett, M. J. et al. Chemical optimization of selective Pseudomonas aeruginosa LasB elastase inhibitors and their impact on LasB-mediated activation of IL-1β in cellular and animal infection models. ACS Infect. Dis. https://doi.org/10.1021/acsinfecdis.2c00418 (2023).
doi: 10.1021/acsinfecdis.2c00418
pubmed: 36669138
pmcid: 9926489
Lozano, C., Azcona-Gutiérrez, J. M., Van Bambeke, F. & Sáenz, Y. Great phenotypic and genetic variation among successive chronic Pseudomonas aeruginosa from a cystic fibrosis patient. PLoS One 13, e0204167 (2018).
pubmed: 30212579
pmcid: 6136817
Bragonzi, A. et al. Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. Am. J. Respir. Crit. Care Med. 180, 138–145 (2009).
pubmed: 19423715
Häussler, S., Tümmler, B., Weissbrodt, H., Rohde, M. & Steinmetz, I. Small-colony variants of Pseudomonas aeruginosa in cystic fibrosis. Clin. Infect. Dis. 29, 621–625 (1999).
pubmed: 10530458
Evans, T. J. Small colony variants of Pseudomonas aeruginosa in chronic bacterial infection of the lung in cystic fibrosis. Future Microbiol. 10, 231–239 (2015).
pubmed: 25689535
Malone, J. Role of small colony variants in persistence of Pseudomonas aeruginosa infections in cystic fibrosis lungs. Infect. Drug Resist. 8, 237–247 (2015).
pubmed: 26251621
pmcid: 4524453
Hassuna, N. A., Mandour, S. A. & Mohamed, E. S. Virulence constitution of multi-drug-resistant Pseudomonas aeruginosa in upper Egypt. Infect. Drug Resist. 13, 587–595 (2020).
pubmed: 32110069
pmcid: 7036984
Mapipa, Q., Digban, T. O., Nnolim, N. E. & Nwodo, U. U. Antibiogram profile and virulence signatures of Pseudomonas aeruginosa isolates recovered from selected agrestic hospital effluents. Sci. Rep. 11, 11800 (2021).
pubmed: 34083705
pmcid: 8175747
Asadpour, L. Antimicrobial resistance, biofilm-forming ability and virulence potential of Pseudomonas aeruginosa isolated from burn patients in northern Iran. J. Glob. Antimicrob. Resist. 13, 214–220 (2018).
pubmed: 29421318
Lanotte, P. et al. Genetic features of Pseudomonas aeruginosa isolates from cystic fibrosis patients compared with those of isolates from other origins. J. Med. Microbiol. 53, 73–81 (2004).
pubmed: 14663109
Hilliam, Y. et al. Pseudomonas aeruginosa adaptation and diversification in the non-cystic fibrosis bronchiectasis lung. Eur. Respir. J. 49, 1602108 (2017).
pubmed: 28446558
pmcid: 5898933
Hoffman, L. R. et al. Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression. J. Cyst. Fibros. 8, 66–70 (2009).
pubmed: 18974024
Hogardt, M. & Heesemann, J. Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung. Int. J. Med. Microbiol. 300, 557–562 (2010).
pubmed: 20943439
Feltner, J. B. et al. LasR variant cystic fibrosis isolates reveal an adaptable quorum-sensing hierarchy in Pseudomonas aeruginosa. MBio 7, e01513-16 (2016).
pubmed: 27703072
pmcid: 5050340
Zupetic, J. et al. Elastase activity from Pseudomonas aeruginosa respiratory isolates and ICU mortality. Chest 160, 1624–1633 (2021).
pubmed: 33878342
pmcid: 8628173
Kalferstova, L., VilimovskaDedeckova, K., Antuskova, M., Melter, O. & Drevinek, P. How and why to monitor Pseudomonas aeruginosa infections in the long term at a cystic fibrosis centre. J. Hosp. Infect. 92, 54–60 (2016).
pubmed: 26597636
Hoo, Z. H. et al. Understanding Pseudomonas status among adults with cystic fibrosis: A real-world comparison of the Leeds criteria against clinicians’ decision. Eur. J. Clin. Microbiol. Infect. Dis. 37, 735–743 (2018).
pubmed: 29307004
pmcid: 5978898
Waine, D. J., Honeybourne, D., Smith, E. G., Whitehouse, J. L. & Dowson, C. G. Cross-sectional and longitudinal multilocus sequence typing of Pseudomonas aeruginosa in cystic fibrosis sputum samples. J. Clin. Microbiol. 47, 3444–3448 (2009).
pubmed: 19710263
pmcid: 2772629
Burns, J. L. et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J. Infect. Dis. 183, 444–452 (2001).
pubmed: 11133376
La Rosa, R., Rossi, E., Feist, A. M., Johansen, H. K. & Molin, S. Compensatory evolution of Pseudomonas aeruginosa’s slow growth phenotype suggests mechanisms of adaptation in cystic fibrosis. Nat. Commun. 12, 3186 (2021).
pubmed: 34045458
pmcid: 8160344
Saint-Criq, V. et al. Pseudomonas aeruginosa LasB protease impairs innate immunity in mice and humans by targeting a lung epithelial cystic fibrosis transmembrane regulator-IL-6-antimicrobial-repair pathway. Thorax 73, 49–61 (2018).
pubmed: 28790180
Bastaert, F. et al. Pseudomonas aeruginosa LasB subverts alveolar macrophage activity by interfering with bacterial killing through downregulation of innate immune defense, reactive oxygen species generation, and complement activation. Front. Immunol. 9, 1675 (2018).
pubmed: 30083156
pmcid: 6064941
Sun, J. et al. The Pseudomonas aeruginosa protease LasB directly activates IL-1β. EBioMedicine 60, 102984 (2020).
pubmed: 32979835
pmcid: 7511813
Hennemann, L. C. et al. LasR-deficient Pseudomonas aeruginosa variants increase airway epithelial mICAM-1 expression and enhance neutrophilic lung inflammation. PLOS Pathog. 17, e1009375 (2021).
pubmed: 33690714
pmcid: 7984618
D’Argenio, D. A. et al. Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients: Pseudomonas lasR mutants in CF. Mol. Microbiol. 64, 512–533 (2007).
pubmed: 17493132
pmcid: 2742308
Consensus conference. Management of patients with cystic fibrosis. Pulmonary disease and infection Guidelines. Société Française de Pédiatrie. Agance Nationale d’Accréditation et d’Evaluation en Santé. https://www.has-sante.fr/jcms/c_272206/en/management-of-patients-with-cystic-fibrosis-pulmonary-disease-and-infection (2003).
Comité de l’Antibiogramme. Recommandations 2015. Socitété Française de Microbiologie (European Committee on Antimicrobial Susceptibility Testing, 2015).
Curran, B., Jonas, D., Grundmann, H., Pitt, T. & Dowson, C. G. Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa. J. Clin. Microbiol. 42, 5644–5649 (2004).
pubmed: 15583294
pmcid: 535286
Jolley, K. A., Bray, J. E. & Maiden, M. C. J. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. Wellcome Open Res. 3, 124 (2018).
pubmed: 30345391
pmcid: 6192448
R Core Team. R: A language and environment for statistical computing. https://www.R-project.org/ (Foundation for Statistical Computing, 2022).
Kassambara, A. ggpubr: ‘ggplot2’ Basde Publication Ready Plots. R Package Version 0.4.0 (2020).
Ogle, D. H., Doll, J. C., Wheeler, P. & Dinno, A. FSA: Fisheries Stock Analysis. R package version 0.9.3 (2022).
Kaplan, J. fastDummies: Fast Creation of Dummy (Binary) Columns and Rows from Categorical Variables (2020).
Rohart, F., Gautier, B., Singh, A. & LêCao, K.-A. mixOmics: An R package for ‘omics feature selection and multiple data integration. PLoS Comput. Biol. 13, e1005752 (2017).
pubmed: 29099853
pmcid: 5687754